Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cisplatin As First-line Therapy For Metastatic Breast Cancer.

G. Sledge, P. Loehrer, B. Roth, L. Einhorn
Published 1988 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase II studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47%), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.
This paper references



This paper is referenced by
10.7314/APJCP.2013.14.6.3711
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
C. Erten (2013)
Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
U. Klaassen (1997)
10.3390/PR8091193
Analysis and Anticancer Effects of Active Compounds from Spatholobi Caulis in Human Breast Cancer Cells
H. Phung (2020)
SALVAGE CHEMO THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) IN ADVANCED BREAST CANCER
D. M. (2020)
10.1007/BF02658930
Chemotherapie des metastasierenden Mammakarzinoms
H. Hausmaninger (2007)
10.1080/1120009X.1991.11739092
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
P. Queirolo (1991)
10.1053/BBMT.2001.V7.PM11400951
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
G. Somlo (2001)
10.1080/15384047.2015.1095400
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
Q. Li (2015)
10.3171/FOC.2006.20.4.3
Management of malignant glioma: steady progress with multimodal approaches.
L. Ashby (2006)
10.1002/1097-0142(19930801)72:3<771::AID-CNCR2820720322>3.0.CO;2-9
Phase II evaluation of carboplatin and VP‐16 for patients with metastatic breast cancer and only one prior chemotherapy regimen
L. Barker (1993)
10.1200/JCO.1999.17.5.1397
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
M. Costanza (1999)
10.1200/JCO.1996.14.4.1185
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
K. Gelmon (1996)
10.3390/cancers10120506
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
E. Nicolas (2018)
10.3816/CBC.2005.N.003
Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.
J. Hurley (2005)
10.1007/s00280-008-0709-7
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer
M. Ruiz (2008)
10.1080/02652048.2016.1228708
New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation
A. Chudecka-Głaz (2016)
10.1055/B-0034-73892
16 Breast Cancer
E. Lin (2009)
10.1093/JNCI/DJH156
HERe-2 stay: the continuing importance of translational research in breast cancer.
G. Sledge (2004)
10.1097/00000421-199906000-00018
Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer.
A. Shamseddine (1999)
10.1016/S1359-6349(05)80272-1
Adjuvant treatment of early breast cancer
L. D. Lago (2005)
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
A. Tolcher (1996)
10.1097/00000421-199604000-00007
Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer.
S. Remick (1996)
SALVAGE CHEMO THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) IN ADVANCED BREAST CANCER
D. M. (2020)
10.1093/ANNONC/MDG171
A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.
K. Gelmon (2003)
10.1016/J.BREAST.2004.08.017
First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
M. Vassilomanolakis (2005)
10.1016/S0093-7754(01)90190-3
The platinum agents: a role in breast cancer treatment?
J. Crown (2001)
10.1371/journal.pone.0130286
Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
Z. Jin (2015)
10.1159/000097945
A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer
A. Shamseddine (2006)
10.12809/HKJR1515321
Treatment horizons for triple-negative breast cancer
W. Yeo (2015)
Emblica extract prevents cisplatin-induced apoptosis in dermal papilla fibroblasts
S. Luanpitpong (2008)
10.1016/j.maturitas.2009.06.010
Triple-negative breast cancer: novel therapies and new directions.
S. Pal (2009)
10.1200/JCO.2002.06.164
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
L. Zelek (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar